Skip to content

Woodsmoke Particulate + Hypertonic Saline

Phase I/II Randomized Cross-over Study of Hypertonic Saline on Airway Inflammatory Response to Inhaled Wood Smoke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03851406
Acronym
Smokeysal
Enrollment
9
Registered
2019-02-22
Start date
2019-08-01
Completion date
2024-09-12
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Inflammation

Brief summary

Deployment of military personnel has been associated with increased respiratory illness likely due, in part, to inhalation of unusual particulate matter (PM), such as from burn pits. Inflammation is a key initial response to inhaled particulates. The investigator has developed a protocol using inhaled wood smoke particles (WSP) as a way to study PM-induced airway inflammation. Exposure to wood smoke particles causes symptoms, even in healthy people, such as eye irritation, cough, shortness of breath, and increased mucous production. The purpose of this research study is to see if a single treatment of inhaled hypertonic saline (HS) can diminish this PM-induced airway inflammation by rapidly clearing the WSP inhaled particles from airway surfaces. The exposure will be 500 ug/m³ of WSP for 2 hours, with intermittent exercise on a bicycle and rest. The wood is burned in a typical wood stove and piped into the chamber.

Detailed description

Military deployment is associated with exposure to novel particulate matter (PM), such as from burn pits, aeroallergens, and increased cigarette consumption. War fighters exposed to these inhalational exposures exhibit immediate and chronic respiratory morbidity. For example, military service personnel surveyed in both the Republic of Korea (ROK) and Kabul, Afghanistan reported a general increase in respiratory morbidity, including asthma and chronic bronchitis, associated with their deployment. Air contaminants in the ROK were characterized by elevated levels of both PM 0.5-2.5 and PM 2.5-10. Similarly, exposures in Kabul were characterized by multiple airborne PM exposures, including those from burn pits. Burn pit PM includes metals, bioaerosols, organic by-products, and biomass combustion particles. These findings indicate that inhaled PM is a likely cause of respiratory morbidity in the field. Inflammation is a key initial response to inhaled particulates. Wood smoke particles (WSP) serve as a model agent to study PM-induced bronchitis. WSP inhalation generates reactive oxidant (and nitrosative) species which cause local injury of airway epithelial cells and release of damage-associated molecular patterns (DAMPs) that activate toll-like receptors (TLR) and interleukin 1 (IL-1)-mediated innate immune responses by resident airway macrophages. Contamination of PM with bioaerosols, which contain lipopolysaccharide (LPS), also activates innate immune responses through toll-like receptor 4 (TLR4) activation of resident airway macrophages. These complementary processes result in recruitment of neutrophils (PMN), which mediate luminal airway inflammation with release of toxic mediators such as neutrophil elastase and myeloperoxidase that promote acute and chronic bronchitis. Therefore, mitigation of PM-induced airway neutrophilic inflammation should be a key focus in order to reduce the respiratory morbidity of military personnel. The investigators have studied a number of pro-inflammatory inhaled agents, such as nebulized LPS, ozone (O3), and WSP, as models of acute neutrophilic bronchitis against which to test a number of therapeutic agents. To this effect, the investigators have reported that inhaled fluticasone inhibits O3-induced and LPS-induced neutrophilic inflammation, and that parenteral anakinra and oral gamma-tocopherol inhibit neutrophilic responses to inhaled LPS. In addition to agents with inherent anti-inflammatory and anti-oxidant properties, rapid clearance of inhaled particles from airway surfaces is a complementary approach to reduce PM-induced airway inflammation. This can be assessed through the measurement of mucociliary clearance (MCC). MCC is dependent on airway secretory cells and submucosal glands that produce a mucin-rich fluid layer on the airway surface and ciliated cells that hydrate and propel mucus out of the lung and into the upper airway. Rates of MCC are dependent on ciliary beat frequency, hydration, and the rheologic properties of mucus. In vitro studies have demonstrated that HS, through an osmotic effect on airway surfaces, improved hydration and mucus rheologic properties, and accelerated mucus transport rates. In addition, the data over the last 30 years has shown that inhaled hypertonic saline (HS) plus cough is the most effective method for acutely clearing the bronchial airways of inhaled, deposited particles. The combined effect is greater than either HS or cough alone. In the studies of asthmatics, the investigators examined the ability of a single HS treatment with a coached cough maneuver to acutely clear radiolabeled Tc99m sulfur colloid particles from airways following LPS exposure. Following HS inhalation and cough clearance maneuvers developed to recover sputum samples for analysis, the investigators observed a rapid clearance of \>50% of the inhaled radiolabelled particles. The investigators hypothesize that if other pro-inflammatory particles (PMs, burn pit particles) were cleared similarly via HS-induced acceleration of MCC shortly after exposure, there would be reductions in acute PM-induced inflammation. Thus, in this study, the investigators will assess the effectiveness of inhaled 5% HS, a dose well tolerated by asthmatics at baseline and after inhaled LPS/allergen challenges for sputum induction, in mitigating WSP-induced airway neutrophilic inflammation in healthy volunteers. Normal saline 0.9% (NS) is not going to be used as a placebo treatment in this study, as inhalation of NS itself impacts the rheologic properties of mucus and MCC and thus would not be a suitable placebo. The investigators will, therefore, compare treatment with 5% HS to no receiving no treatment following WSP exposure.

Interventions

Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.

OTHERNo treatment

No inhaled treatment will be provided immediately following exit from the wood smoke chamber.

Sponsors

United States Department of Defense
CollaboratorFED
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

To determine the efficacy of nebulized 5% hypertonic saline (HS) (v. no treatment) in mitigating wood smoke particulate (WSP)-induced neutrophilic airway inflammation, assessed via sputum %polymorphonuclear leukocytes (PMNs), in healthy adults 4 hours post WSP exposure.

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-45 years, inclusive, of both genders * Negative pregnancy test for females who are not s/p hysterectomy with oophorectomy * No history of episodic wheezing, chest tightness, or shortness of breath consistent with asthma, or physician-diagnosed asthma. * forced expiratory volume at one second (FEV1) of at least 80% of predicted and FEV1/forced vital capacity (FVC) ratio of \>0.70. * Oxygen saturation of \>93% * Ability to provide an induced sputum sample. * Subject must demonstrate a \>10% increase in sputum %PMNs 6 hours following inhaled WSP exposure, when compared to baseline sputum (to be completed in a separate protocol #15-1775). * Proof of vaccination to SARS-CoV-2 based on public health guidelines at time of inclusion

Exclusion criteria

* Clinical contraindications: * Any chronic medical condition considered by the PI as a contraindication to the exposure study including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid disease, history of chronic infections/immunodeficiency. * Viral upper respiratory tract infection within 4 weeks of challenge. * Any acute infection requiring antibiotics within 4 weeks of exposure or fever of unknown origin within 4 weeks of challenge. * Abnormal physical findings at the baseline visit, including but not limited to abnormalities on auscultation, temperature of 37.8° C, Systolic BP \> 150mm Hg or \< 85 mm Hg; or Diastolic BP \> 90 mm Hg or \< 50 mm Hg, or pulse oximetry saturation reading less than 93%. * Physician diagnosis of asthma * If there is a history of allergic rhinitis, subjects must be asymptomatic of allergic rhinitis at the time of study enrollment. * Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements. * Medications which may impact the results of the WSP exposure, interfere with any other medications potentially used in the study (to include steroids, beta antagonists, non-steroidal anti-inflammatory agents) * Cigarette smoking \> 1 pack per month * Unwillingness to use reliable contraception if sexually active (IUD, birth control pills/patch, condoms). * Use of immunosuppressive or anticoagulant medications including routine use of NSAIDS. Oral contraceptives are acceptable, as are antidepressants and other medications may be permitted if, in the opinion of the investigator, the medication will not interfere with the study procedures or compromise safety and if the dosage has been stable for 1 month. * Orthopedic injuries or impediments that would preclude bicycle or treadmill exercise. * Inability to avoid NSAIDS, Multivitamins, Vitamin C or E or herbal supplements. * Allergy/sensitivity to study drugs or their formulations * Positive COVID-19 test in the past 90 days. * Pregnant/lactating women and children (\< 18 years as this is age of majority in North Carolina) will also be excluded since the risks associated with WSP exposure to the fetus or child, respectively, are unknown and cannot be justified for this non-therapeutic protocol. Individuals over 45 years of age will not be included due to the increased possibility of co-morbidities and need for prohibited medications. * Inability or unwillingness of a participant to give written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline to 24 Hours in Sputum Percent NeutrophilsBaseline, 24 hours post WSP exposureChange in sputum percent neutrophils from baseline to 24 hours post WSP exposure
Change From Baseline to 4 Hours in Sputum Percent NeutrophilsBaseline, 4 hours post WSP exposureChange in sputum percent neutrophils from baseline to 4 hours post WSP exposure

Secondary

MeasureTime frameDescription
Change in Number of Sputum NeutrophilsBaseline, 4 and 24 hours post WSP exposureNeutrophil numbers/mg compared at 4 and 24 hours post WSP exposure with respect to Baseline.
Change in Number of Sputum EosinophilsBaseline, 4 and 24 hours post WSP exposureEosinophil numbers/mg compared at 4 and 24 hours post WSP exposure with respect to Baseline.
Change in Percent Sputum EosinophilsBaseline, 4 and 24 hours post WSP exposurePercent eosinophils compared at 4 and 24 hours post WSP exposure with respect to Baseline.
Change in Interleukin-6Baseline, 4 and 24 hours post WSP exposureInterleukin-6 via Mesoscale platform (pg/mL) compared at 4 and 24 hours post WSP exposure with respect to Baseline.
Change in Interleukin-8Baseline, 4 and 24 hours post WSP exposureInterleukin-8 via Mesoscale platform (pg/mL) compared at 4 and 24 hours post WSP exposure with respect to Baseline.
Change in Interleukin-1bBaseline, 4 and 24 hours post WSP exposureInterleukin-1β via the Mesoscale platform (pg/mL) compared at 4 and 24 hours post-WSP exposure with respect to Baseline.
Change in Tumor Necrosis Factor AlphaBaseline, 4 and 24 hours post WSP exposureTumor Necrosis Factor Alpha via Mesoscale platform (pg/mL) compared at 4 and 24 hours post WSP exposure with respect to Baseline.

Other

MeasureTime frameDescription
Mucociliary Clearance (MCC)4 hours post WSP exposure]4 hours post WSP exposure, the MCC is done. A whole lung region of interest (ROI) bordering the right lung is used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. Labeled particle counts are measured over a 2 hour period to determine the fraction of initial particle counts remaining. From this data, the investigators will determine the percentage of labeled particles cleared from the lung during the 2 hour observation period.

Countries

United States

Participant flow

Participants by arm

ArmCount
5% Hypertonic Saline, Then No Inhaled Treatment
Participants will receive 5% Hypertonic Saline following WSP exposure. After a 2-week washout period, participants will receive no treatment following WSP exposure. 5% Hypertonic Saline: Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver. No treatment: No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
4
No Inhaled Treatment, Then 5% Hypertonic Saline
Participants will receive no inhaled treatment following WSP exposure. After a 2-week washout period, participants will receive 5% Hypertonic Saline following WSP exposure. 5% Hypertonic Saline: Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver. No treatment: No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
3
Total7

Baseline characteristics

Characteristic5% Hypertonic Saline, Then No Inhaled TreatmentNo Inhaled Treatment, Then 5% Hypertonic SalineTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
4 Participants3 Participants7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
4 Participants3 Participants7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
3 Participants2 Participants5 Participants
Region of Enrollment
United States
4 Participants3 Participants7 Participants
Sex: Female, Male
Female
3 Participants2 Participants5 Participants
Sex: Female, Male
Male
1 Participants1 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 60 / 6
other
Total, other adverse events
1 / 61 / 6
serious
Total, serious adverse events
0 / 60 / 6

Outcome results

Primary

Change From Baseline to 24 Hours in Sputum Percent Neutrophils

Change in sputum percent neutrophils from baseline to 24 hours post WSP exposure

Time frame: Baseline, 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an inadequate cell differential slide. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureValue (MEDIAN)
5% Hypertonic SalineChange From Baseline to 24 Hours in Sputum Percent Neutrophils17 percent neutrophils
No Inhaled TreatmentChange From Baseline to 24 Hours in Sputum Percent Neutrophils29 percent neutrophils
p-value: >0.99Wilcoxon (Mann-Whitney)
Primary

Change From Baseline to 4 Hours in Sputum Percent Neutrophils

Change in sputum percent neutrophils from baseline to 4 hours post WSP exposure

Time frame: Baseline, 4 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an inadequate cell differential slide. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureValue (MEDIAN)
5% Hypertonic SalineChange From Baseline to 4 Hours in Sputum Percent Neutrophils-0.04 percent neutrophils
No Inhaled TreatmentChange From Baseline to 4 Hours in Sputum Percent Neutrophils-0.5 percent neutrophils
p-value: >0.99Wilcoxon (Mann-Whitney)
Secondary

Change in Interleukin-1b

Interleukin-1β via the Mesoscale platform (pg/mL) compared at 4 and 24 hours post-WSP exposure with respect to Baseline.

Time frame: Baseline, 4 and 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an insufficient sample quantity. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureGroupValue (MEDIAN)
5% Hypertonic SalineChange in Interleukin-1b4 hours post WSP exposure0.95 pg/mL
5% Hypertonic SalineChange in Interleukin-1b24 hours post WSP exposure0.41 pg/mL
No Inhaled TreatmentChange in Interleukin-1b4 hours post WSP exposure-2.5 pg/mL
No Inhaled TreatmentChange in Interleukin-1b24 hours post WSP exposure-0.58 pg/mL
Comparison: 4 hours post WSP exposurep-value: 0.88Wilcoxon (Mann-Whitney)
Comparison: 24 hours post WSP exposurep-value: >0.99Wilcoxon (Mann-Whitney)
Secondary

Change in Interleukin-6

Interleukin-6 via Mesoscale platform (pg/mL) compared at 4 and 24 hours post WSP exposure with respect to Baseline.

Time frame: Baseline, 4 and 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an insufficient sample quantity. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureGroupValue (MEDIAN)
5% Hypertonic SalineChange in Interleukin-624 hours post WSP exposure0.73 pg/mL
5% Hypertonic SalineChange in Interleukin-64 hours post WSP exposure0.94 pg/mL
No Inhaled TreatmentChange in Interleukin-624 hours post WSP exposure-1.9 pg/mL
No Inhaled TreatmentChange in Interleukin-64 hours post WSP exposure-1.2 pg/mL
Comparison: 4 hours post WSP exposurep-value: 0.88Wilcoxon (Mann-Whitney)
Comparison: 24 hours post WSP exposurep-value: 0.25Wilcoxon (Mann-Whitney)
Secondary

Change in Interleukin-8

Interleukin-8 via Mesoscale platform (pg/mL) compared at 4 and 24 hours post WSP exposure with respect to Baseline.

Time frame: Baseline, 4 and 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an insufficient sample quantity. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureGroupValue (MEDIAN)
5% Hypertonic SalineChange in Interleukin-84 hours post WSP exposure-37 pg/mL
5% Hypertonic SalineChange in Interleukin-824 hours post WSP exposure65 pg/mL
No Inhaled TreatmentChange in Interleukin-84 hours post WSP exposure-138 pg/mL
No Inhaled TreatmentChange in Interleukin-824 hours post WSP exposure82 pg/mL
Comparison: 4 hours post WSP exposurep-value: >0.99Wilcoxon (Mann-Whitney)
Comparison: 24 hours post WSP exposurep-value: >0.99Wilcoxon (Mann-Whitney)
Secondary

Change in Number of Sputum Eosinophils

Eosinophil numbers/mg compared at 4 and 24 hours post WSP exposure with respect to Baseline.

Time frame: Baseline, 4 and 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an inadequate cell differential slide. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureGroupValue (MEDIAN)
5% Hypertonic SalineChange in Number of Sputum Eosinophils4 hours post WSP exposure0 Eosinophils/mg
5% Hypertonic SalineChange in Number of Sputum Eosinophils24 hours post WSP exposure-0.10 Eosinophils/mg
No Inhaled TreatmentChange in Number of Sputum Eosinophils4 hours post WSP exposure0 Eosinophils/mg
No Inhaled TreatmentChange in Number of Sputum Eosinophils24 hours post WSP exposure0.45 Eosinophils/mg
Comparison: 4 hours post WSP exposurep-value: 0.38Wilcoxon (Mann-Whitney)
Comparison: 24 hours post WSP exposurep-value: 0.38Wilcoxon (Mann-Whitney)
Secondary

Change in Number of Sputum Neutrophils

Neutrophil numbers/mg compared at 4 and 24 hours post WSP exposure with respect to Baseline.

Time frame: Baseline, 4 and 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an inadequate cell differential slide. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureGroupValue (MEDIAN)
5% Hypertonic SalineChange in Number of Sputum Neutrophils4 hours post WSP exposure0.40 Neutrophils/mg
5% Hypertonic SalineChange in Number of Sputum Neutrophils24 hours post WSP exposure9.5 Neutrophils/mg
No Inhaled TreatmentChange in Number of Sputum Neutrophils4 hours post WSP exposure19 Neutrophils/mg
No Inhaled TreatmentChange in Number of Sputum Neutrophils24 hours post WSP exposure79 Neutrophils/mg
Comparison: 4 hours post WSP exposurep-value: >0.99Wilcoxon (Mann-Whitney)
Comparison: 24 hours post WSP exposurep-value: >0.99Wilcoxon (Mann-Whitney)
Secondary

Change in Percent Sputum Eosinophils

Percent eosinophils compared at 4 and 24 hours post WSP exposure with respect to Baseline.

Time frame: Baseline, 4 and 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an inadequate cell differential slide. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureGroupValue (MEDIAN)
5% Hypertonic SalineChange in Percent Sputum Eosinophils24 hours post WSP exposure0.00 percent eosinophils
5% Hypertonic SalineChange in Percent Sputum Eosinophils4 hours post WSP exposure0.33 percent eosinophils
No Inhaled TreatmentChange in Percent Sputum Eosinophils24 hours post WSP exposure0.00 percent eosinophils
No Inhaled TreatmentChange in Percent Sputum Eosinophils4 hours post WSP exposure0.00 percent eosinophils
Comparison: 4 hours post WSP exposurep-value: 0.25Wilcoxon (Mann-Whitney)
Comparison: 24 hours post WSP exposurep-value: 0.63Wilcoxon (Mann-Whitney)
Secondary

Change in Tumor Necrosis Factor Alpha

Tumor Necrosis Factor Alpha via Mesoscale platform (pg/mL) compared at 4 and 24 hours post WSP exposure with respect to Baseline.

Time frame: Baseline, 4 and 24 hours post WSP exposure

Population: An attempt was made to analyze samples for all participants; although some samples had an insufficient sample quantity. Data are reported for all samples that yielded data for each endpoint and at each time.

ArmMeasureGroupValue (MEDIAN)
5% Hypertonic SalineChange in Tumor Necrosis Factor Alpha4 hours post WSP exposure0.00 pg/mL
5% Hypertonic SalineChange in Tumor Necrosis Factor Alpha24 hours post WSP exposure0.05 pg/mL
No Inhaled TreatmentChange in Tumor Necrosis Factor Alpha4 hours post WSP exposure-0.35 pg/mL
No Inhaled TreatmentChange in Tumor Necrosis Factor Alpha24 hours post WSP exposure0.22 pg/mL
Comparison: 4 hours post WSP exposurep-value: 0.75Wilcoxon (Mann-Whitney)
Comparison: 24 hours post WSP exposurep-value: 0.38Wilcoxon (Mann-Whitney)
Other Pre-specified

Mucociliary Clearance (MCC)

4 hours post WSP exposure, the MCC is done. A whole lung region of interest (ROI) bordering the right lung is used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. Labeled particle counts are measured over a 2 hour period to determine the fraction of initial particle counts remaining. From this data, the investigators will determine the percentage of labeled particles cleared from the lung during the 2 hour observation period.

Time frame: 4 hours post WSP exposure]

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026